Teva’s Ellis Is New BBA Chair
Teva Welcomes Decision Of British Biosimilars Association
Teva UK’s director of secondary care, Andrew Ellis, who has been a member of the British Biosimilars Association’s steering group, has now been appointed as its new chair.
You may also be interested in...
Upsher-Smith has strengthened its US generics portfolio with three new launches that will compete in a combined market worth nearly $102.5m.
Amgen has filed a US patent-infringement lawsuit against Pfizer’s Hospira over its biosimilar pegfilgrastim rival to Neulasta.
Sawai’s sales increased on the back of a good performance from recently-launched products in the first nine months of its financial year. However, given the competitive environment the Japanese company is continuing to stick to its full-year forecasts.